Similar Papers

Paper Title
Journal
Date
Author
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
...
Journal of the National Comprehensive Cancer Network | VOL. 19
, et. al. ...
01 Dec 2021
Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting.
Jacob Sands ... Janakiraman Subramanian
Frontiers in oncology | VOL. 13
Jacob Sands, et. al.Jacob Sands ... Janakiraman Subramanian
22 Dec 2023
Non–Small Cell Lung Cancer
David S Ettinger ...
Journal of the National Comprehensive Cancer Network | VOL. 8
David S Ettinger, et. al.David S Ettinger ...
01 Jul 2010
Small Cell Lung Cancer
Gregory P Kalemkerian ...
Journal of the National Comprehensive Cancer Network | VOL. 11
Gregory P Kalemkerian, et. al.Gregory P Kalemkerian ...
01 Jan 2013
View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title
Journal
Date
Author
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Alessio Cortellini ... Biagio Ricciuti
Journal for ImmunoTherapy of Cancer | VOL. 13
Alessio Cortellini, et. al.Alessio Cortellini ... Biagio Ricciuti
04 Feb 2025
Modulating lipid metabolism improves tumor immunotherapy
Yu Ping ... Yi Zhang
Journal for ImmunoTherapy of Cancer | VOL. 13
Yu Ping, et. al.Yu Ping ... Yi Zhang
04 Feb 2025
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis
Cameron Wood ... Neal Ready
Journal for ImmunoTherapy of Cancer | VOL. 13
Cameron Wood, et. al.Cameron Wood ... Neal Ready
04 Feb 2025
Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma
Thomas Eigentler ... Ulrike Gnad-Vogt
Journal for ImmunoTherapy of Cancer | VOL. 13
Thomas Eigentler, et. al.Thomas Eigentler ... Ulrike Gnad-Vogt
04 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.